Wart

Microsoft, Nvidia, AWS and Adobe CEO Shantanu Narayen Nab Top Honors; Legacy Social Media Named Biggest Tech Flop in Constellation Research 2023 Enterprise Awards

Retrieved on: 
Wednesday, December 13, 2023
Constellation, Quantum, Initial public offering, PALO, Generative, Organization, Social network, Wart, Firefly, Synthetic media, Government, Speed, Once, Research, OpenAI, Social media, Qaa, Databricks, Partnership, AI, Microsoft, Snowflake, Shantanu Narayen, AWS, Film industry, Adobe, Nvidia

PALO ALTO, Calif., Dec. 13, 2023 /PRNewswire-PRWeb/ -- Shantanu Narayen, CEO of Adobe, was named as Enterprise Technology CEO of the Year in Constellation Research's annual 2023 Enterprise Awards. Narayen was singled out for his strength in leadership, specifically for leaning into AI and Firefly when critics said AI would kill creative jobs.

Key Points: 
  • PALO ALTO, Calif., Dec. 13, 2023 /PRNewswire-PRWeb/ -- Shantanu Narayen, CEO of Adobe, was named as Enterprise Technology CEO of the Year in Constellation Research's annual 2023 Enterprise Awards.
  • The distinguished list of technology hits and misses was announced today highlighting the biggest accomplishments and downfalls in 2023.
  • This is the fifth annual release of the Enterprise Awards, decided solely by Constellation Research's industry analysts and experts.
  • The Biggest Technology Flop for 2023 goes to "The Slow and Painful Death of Legacy Social Media", an "honor" proven out by the crash and demise of once-hot solutions.

Frontier Dermatology Expands Community Reach with New Office in Sequim, WA Led by Renowned Dermatologist Dr. Heidi Hermes Shantz

Retrieved on: 
Wednesday, December 6, 2023
Skin cancer, Dermatology, Psoriasis, Dermatitis, Patient, Wart, Pacific Northwest, Acne, Veterinary medicine, Hospital

PORTLAND, Ore. and SEATTLE, Dec. 6, 2023 /PRNewswire/ -- Frontier Dermatology, the leading authority on medical and cosmetic skin care in the Pacific Northwest, is delighted to announce the grand opening of a brand-new, state-of-the-art dermatology clinic in Sequim, Washington on December 7. The new office, located at 565 Eureka Way, will be led by Dr. Heidi Hermes Shantz, an esteemed dermatologist with long-standing ties to the community.

Key Points: 
  • The new office, located at 565 Eureka Way, will be led by Dr. Heidi Hermes Shantz, an esteemed dermatologist with long-standing ties to the community.
  • The Sequim office will provide patients with access to a comprehensive range of dermatological services, including general dermatology for conditions such as acne, eczema, and psoriasis, and select cosmetic dermatology services.
  • New and existing patients may schedule an appointment with Dr. Heidi Hermes Shantz or Haley Gravely by contacting 360-749-8064 (p); 360-994-4975 (f); or by visiting www.FrontierDermatology.com .
  • For more information about Frontier Dermatology and its comprehensive suite of medical and cosmetic skin solutions, please visit www.FrontierDermatology.com .

Veradermics Co-Founder and CEO, Reid Waldman, Named to the 2023 Forbes "30 Under 30" Healthcare List

Retrieved on: 
Wednesday, November 29, 2023
Entrepreneurship, Wart, Clinical trial, Medicine, American Academy, Cedars-Sinai Medical Center, University, Pattern hair loss, Atopic dermatitis, Therapy, American Academy of Dermatology, Health care, Health, Skin, Physician, Publication, Hair loss, Molluscum contagiosum, Pharmaceutical industry, Dermatology

NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has been included in the 2023 Forbes "30 Under 30" Healthcare list, recognizing leading scientists and entrepreneurs developing innovative solutions that address some of healthcare's biggest challenges.

Key Points: 
  • Two products of which Waldman is an inventor, including an immune stimulatory microarray for warts and a non-hormonal oral therapeutic for androgenetic alopecia, are currently in clinical trials.
  • In a significant milestone, the company recently announced the dosing of the first patient in a clinical trial for its non-hormonal oral therapeutic for pattern hair loss.
  • In addition to the two therapeutics currently in trials for warts and pattern hair loss, Veradermics pipeline also includes candidates targeting alopecia areata, atopic dermatitis, and molluscum contagiosum.
  • The company expects to advance these additional product candidates into the clinic in 2024.

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023
Priority review, FDA, Ageing, PDUFA, Addition, Rare, Physician, Christophe, SG, MD, Conference, Organization, Doctor of Philosophy, PRV, Primary immunodeficiency, R, Society, Neutropenia, ASH, Wart, WHIM, Disease, ID, WHIM syndrome, Immune system, Research and development, Line, File, Security (finance), New Drug Application, NDA, Safety, Conference call, Patient, Diagnosis, State Administrative Expenses, Pharmaceutical industry, Rare-earth element, Hypogammaglobulinemia, Infection, Myelokathexis

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.
  • The FDA has notified X4 that it does not currently plan to hold an advisory committee meeting to review the filing.
  • Cash, Cash Equivalents, Restricted Cash, and Short-Term Marketable Securities: X4 had $142.7 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2023.
  • The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

Retrieved on: 
Tuesday, October 31, 2023
Priority review, FDA, Ageing, PDUFA, Orphan, Rare, RPD, CXCR4, PRV, Primary immunodeficiency, Wart, WHIM, WHIM syndrome, Immune system, New Drug Application, NDA, Pharmaceutical industry, Hypogammaglobulinemia, Infection, Myelokathexis

BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the United States Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. The FDA granted Priority Review of the mavorixafor NDA, establishing a goal of six months review from the date of acceptance and assigning a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.

Key Points: 
  • The FDA granted Priority Review of the mavorixafor NDA, establishing a goal of six months review from the date of acceptance and assigning a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.
  • “The FDA’s acceptance of our mavorixafor NDA with priority review represents yet another significant step forward towards a potential treatment for those with WHIM syndrome, a rare disease for which there are currently no approved therapies,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Upon FDA approval of a product with RPD designation, the sponsor can receive a Priority Review Voucher that can be used to obtain priority review for a subsequent application or sold to another drug sponsor.
  • The NDA is supported by the results of the global, pivotal, 4WHIM Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome.

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

Retrieved on: 
Tuesday, September 5, 2023
European Hematology Association, File, WHIM, Federation of Clinical Immunology Societies, NDA, CIS, WHIM syndrome, Immune system, EHA, Primary immunodeficiency, Wart, Ageing, Rare, FDA, Pharmaceutical industry, Infection, Myelokathexis, Hypogammaglobulinemia

“The submission of our first NDA is a significant milestone in X4's journey to transform the care of those living with rare immunodeficiencies,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

Key Points: 
  • “The submission of our first NDA is a significant milestone in X4's journey to transform the care of those living with rare immunodeficiencies,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • “We’re excited that this submission moves us one step closer to introducing what could be the first approved product in the U.S. for those with WHIM syndrome.
  • X4 has requested priority review for the application which, if granted, would provide a target FDA review period of six months from the application acceptance for filing date.
  • The NDA submission is supported by the results of the global, pivotal, 4WHIM Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome.

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Retrieved on: 
Tuesday, September 5, 2023
Research, Teens, Infectious Diseases, Children, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, MSD, Hypersensitivity, CIN, Male, Female, Pediatrics, Allergy, Life, Vaccination, CIN1, Human papillomavirus infection, Cancer, MRK, Vulvar cancer, Woman, Head, Month, AIS, Vulvectomy, Merck & Co., CDC, Incidence, Death, PIN, Anal cancer, Cervical cancer, Wart, Vain, Vaginal intraepithelial neoplasia, HPV, VIN, Cervical intraepithelial neoplasia, Anus, NYSE, Disease, Vaccine, Birth control, Recombinant, Merck

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • As part of the primary objective of immunogenicity, data showed sustained HPV-antibody responses at 10 years after the third dose in boys and girls.
  • With the exception of cervical cancer, there is no routinely recommended screening for the detection of HPV-related cancers.

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Retrieved on: 
Thursday, August 10, 2023
Addition, Christophe, Maintenance, ANC, Priority review, Therapy, SG, European Hematology Association, Line, Conference call, Federation of Clinical Immunology Societies, Neutropenia, PIPE, Disclosure, Clinical trial, CIS, Research, Cash, Doctor of Philosophy, ID, Research and development, State Administrative Expenses, Russell, MD, Physician, Patient, WHIM syndrome, Patent, Immune system, Annual Meetings of the International Monetary Fund and the World Bank Group, EHA, Growth, Wart, G-CSF, R, Rare, Restricted, Conference, Safety, Pharmaceutical industry, Cryptocurrency, Bank, Infection, Hypogammaglobulinemia

Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.

Key Points: 
  • Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.
  • X4 is planning to initiate a Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders in the first half of 2024.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast and slide presentation can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Therapy, Table, OrbiMed, WEST, Bank statement, Phase II, Wart, CMC, GAAP, Part, H.262/MPEG-2 Part 2, Dermatology, Patient, Molluscum contagiosum, Part Two, Research, FDA, Carcinoma, Skin, Vaccine, Pharmaceutical industry, Cryptocurrency, Reinsurance, Bank

– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –

Key Points: 
  • – In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –
    WEST CHESTER, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2023.
  • Verrica recognized collaboration revenues of $0.2 million in the second quarter of 2023 and 2022 related to the Clinical Supply Agreement with Torii Pharmaceutical Col, Ltd (Torii).
  • Research and development expenses were $5.7 million in the second quarter of 2023, compared to $3.9 million for the same period in 2022.
  • General and administrative expenses were $5.9 million in the second quarter of 2023, compared to $5.2 million for the same period in 2022.

FDA Approves First Nonprescription Daily Oral Contraceptive

Retrieved on: 
Thursday, July 13, 2023
Vaginal bleeding, Pregnancy, Headache, Syphilis, Laboratoires Pierre Fabre, Bleeding, HIV, Center for Drug Evaluation and Research, Prenatal care, Condom, Cancer, Gonorrhea, Cramp, Hepatitis B, Perrigo, Appetite, Abdominal pain, Dizziness, AIDS, Wart, Risk, Child, Norgestrel, Genital herpes, Vertically transmitted infection, Nausea, Bloating, Chlamydia, Amenorrhea, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Breast cancer, Birth control, Pharmaceutical industry

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Key Points: 
  • Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.
  • "Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research.
  • "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
  • Opill also should not be used together with another hormonal birth control product such as another oral contraceptive tablet, a vaginal ring, a contraceptive patch, a contraceptive implant, a contraceptive injection or an IUD (intra-uterine device).